[A case of systemic sclerosis].

[1]  Ami A. Shah,et al.  Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer , 2018, Annals of the rheumatic diseases.

[2]  E. Hachulla,et al.  Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening , 2017, The Journal of Rheumatology.

[3]  D. Lynch,et al.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.

[4]  L. Dauchet,et al.  Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis , 2014, Arthritis & rheumatology.

[5]  Yuchen Jiao,et al.  Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer , 2014, Science.

[6]  Ami A. Shah,et al.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. , 2010, Arthritis and rheumatism.

[7]  A. Krarup-Hansen,et al.  Scleroderma induced by paclitaxel , 2010, Acta oncologica.

[8]  M. Pujazon,et al.  Diffuse Infiltrative Lung Disease Associated with Flecainide , 2002, Respiration.

[9]  H. Perchet,et al.  Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome , 2000, Acta cardiologica.

[10]  P. Wallemacq,et al.  Flecainide-associated interstitial pneumonitis , 1991, The Lancet.

[11]  J. Cadranel,et al.  Flecainide-associated pneumonitis , 1991, The Lancet.